Crohn's Disease and Colitis Trial, Recruiting NCT06856044 Sponsor: Centre Hospitalier Universitaire de Nīmes Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT06856044
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given their free and informed consent and signed the consent form
  • People who are members or beneficiaries of a health insurance plan
  • People who have a confirmed diagnosis of Crohn's disease, proven through tissue testing
  • People who have had surgical removal of part of the small intestine and colon (ileocolic resection), where the affected area of the bowel can be examined by a camera scope (endoscopy), whether this was their first or a repeat operation
  • People who are currently being treated with a biologic medication, such as infliximab, adalimumab (anti-TNF treatments), vedolizumab, ustekinumab, risankizumab, or another similar biologic therapy
  • People who are able to understand, write, and read French

Who may not be able to join:

  • People who are currently taking part in another interventional research study
  • People who are under legal protection or state guardianship
  • People whose current Crohn's disease treatment includes medications other than the biologic therapies listed (such as infliximab, adalimumab, vedolizumab, ustekinumab, or risankizumab)
  • People who have medical reasons that make surgery unsafe, such as serious heart or blood vessel conditions
  • People who are pregnant, breastfeeding, or in labour

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Martin BERTRAND, CHU de Nimes

Phone: 04 66 68 31 43

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire de Nīmes
Registry
ClinicalTrials.gov
Start date
15 September 2025
Est. completion
1 October 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Post-surgical complication rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov